Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
Akero Therapeutics, Inc
Mazen Noureddin; Juan P Frias; Guy W Neff; K Jean Lucas; Cynthia Behling; Pierre Bedossa; Julie Dubourg; Doreen Chan; Mark Burch; Erica Fong; Brittany de Temple; Matt Minerva; Kim Barrett; Reshma Shringarpure; Erik J Tillman; Timothy Rolph; Andrew Cheng; Kitty Yale